Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma
- Bagot, M.
- Dalle, S.
- Sokol, L.
- Tsianakas, A.
- Musiek, A.
- Ortiz-Romero, P.L.
- Poligone, B.
- Duvic, M.
- Elmets, C.
- Leoni, M.
- Dwyer, K.
- Ito, T.
- Herr, F.
- Kim, Y.H.
ISSN: 1529-8019, 1396-0296
Any de publicació: 2022
Volum: 35
Número: 8
Tipus: Carta